GlycoMimetics, Inc. (NASDAQ:GLYC) announced today the addition of Mark A. Goldberg, M.D. to its Board of Directors. Dr. Goldberg is Executive Vice President, Medical and Regulatory Strategy at Synageva BioPharma Corporation and holds appointments at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He is also an Associate Clinical Professor of Medicine at Harvard Medical School.
Help employers find you! Check out all the jobs and post your resume.
